Physician profile
Bushra Haq
NPI 1780827857
$2,610.09
in general payments reported to CMS, 2019-2025
16 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $132 · 2021: $267 · 2022: $29.47 · 2023: $317 · 2024: $1,375 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,050 · Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,050.00 |
| Food and Beverage | $861.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,254.89 | 2020-2024 | Lynparza, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $642.40 | 2019-2025 | Opdivo |
| Iovance Biotherapeutics, INC. | $120.99 | 2024 | Amtagvi |
| Immunogen, INC. | $83.55 | 2023 | Elahere |
| Illumina, INC. | $79.72 | 2025 | Oncology Testing |
| Tesaro, INC. | $78.07 | 2019 | |
| Abbvie INC. | $68.55 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.50 | 2023 | Lifevest |
| Jazz Pharmaceuticals INC. | $50.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.78 | 2022-2023 | Libtayo |
| Genzyme Corporation | $27.87 | 2022-2023 | |
| Tempus Ai, INC | $27.64 | 2024 | |
| Novartis Pharmaceuticals Corporation | $27.29 | 2023 | |
| Eisai INC. | $26.79 | 2025 | |
| Incyte Corporation | $17.58 | 2025 | Jakafi, Niktimvo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bushra Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.